About this Research Topic
Chronic hepatitis C virus (HCV) infection is one of the leading causes of liver diseases, presenting a heavy burden to global health systems. Fortunately, we are now in the era of potent pan-genotypic direct antiviral agents (DAAs), and we will embrace the HCV elimination era shortly. However, there are some unaddressed real-world issues. For example, many chronic hepatitis C patients, especially those in resource-limited areas and those at a high risk of infection have no access to screening, diagnosis, and treatment. Hepatitis C micro-elimination and cascade of care are in great needs. On the other hand, although the Sustained Virological Response (SVR) is very high, we must face the difficult-to-treat chronic hepatitis C patients, even though some of them have been treated with the potent DAAs. The mechanism and solution should be investigated. Moreover, the long-term outcome of the DAA-cured hepatitis C patients is still worth following up.
In this Research Topic, we aim to provide perspectives and evidence relating to the cost-effective real-world approaches of screening HCV infection, the mechanisms and treatment solutions for the difficult-to-treat chronic hepatitis C patients, and the sensitive surveillance strategies for the patients achieving SVR after DAA therapy.
We welcome submissions of Original Research, Review, Systematic Review, Mini Review, Meta-analysis, Case Report and Perspective articles on the sub-topics below:
· Finding the cost-effective diagnostic strategies to link the potential HCV infectors to cure: experiences from different populations and settings
· The role of the point-of-care anti-HCV and HCV core antigen testing for screening and treatment monitoring
· Difficult-to-treat chronic hepatitis C in the era of potent direct antiviral agents (DAAs): mechanism and solution
· The role of the resistance associated substitution (RAS) in the DAA treatment failure scenarios
· Liver cirrhosis and hepatocellular carcinoma surveillance in the coming post-DAA era
In this Research Topic, we aim to provide perspectives and evidence relating to the cost-effective real-world approaches of screening HCV infection, the mechanisms and treatment solutions for the difficult-to-treat chronic hepatitis C patients, and the sensitive surveillance strategies for the patients achieving SVR after DAA therapy.
We welcome submissions of Original Research, Review, Systematic Review, Mini Review, Meta-analysis, Case Report and Perspective articles on the sub-topics below:
· Finding the cost-effective diagnostic strategies to link the potential HCV infectors to cure: experiences from different populations and settings
· The role of the point-of-care anti-HCV and HCV core antigen testing for screening and treatment monitoring
· Difficult-to-treat chronic hepatitis C in the era of potent direct antiviral agents (DAAs): mechanism and solution
· The role of the resistance associated substitution (RAS) in the DAA treatment failure scenarios
· Liver cirrhosis and hepatocellular carcinoma surveillance in the coming post-DAA era
Keywords: Hepatitis C virus, Chronic hepatitis C, Diagnostic strategy, Direct antiviral agents, Elimination
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
